An article in The Wall Street Journal looks at the changing face of socially responsible investing.
Socially responsible investment funds generally use screens to avoid stocks that they perceive as being objectionable: alcohol and tobacco companies, along with weapons manufacturers are generally excluded from these funds.
But as the funds gather assets and gain a mainstream following -- as investors everywhere become increasingly concerned about issues like global warming -- these funds are finding themselves with more leverage than ever before. They can get meetings with CEOs and use shareholder meetings to voice concerns about issues and drum up support among other shareholders.
As pension funds jump into the mix, issues involving labor and health care also gain prominence.
I'm a big supporter of socially responsible investing but, taken to an extreme, there can be a downside. As these funds gain increased leverage, they can push companies into adopting policies that are reflective of pet causes rather than the broader interests of minority shareholders.
As Milton Friedman wrote, "There is one and only one social responsibility of business -- to use its resources and engage in activities designed to increase its profits so long as it stays within the rules of the game, which is to say, engages in open and free competition without deception or fraud."
While I would argue that that may be extreme, many investors adopt that ideology wholeheartedly and will object to the growing influence of SRI funds.
Last updated: February 10, 2012: 09:07 AM
Hot Stocks
DailyFinance Headlines
- Walmart's New Health Food Push: Is It Too Hard to Swallow?
- Newlyweds, Don't Let the IRS Spoil Your Honeymoon
- Bonds Are a 'Safe' Investment: A Big Lie Gets Even Bigger
- Why Groupon Will Never Be Great Again
- Why Used Car Bargains Are Getting Harder to Find
Benzinga Headlines
- Chesapeake Gently Lets Go of Gas
- How to Profit off Addicts
- The Pepsi Challenge for 8,700 People is to Find a New Job
- How to Profit From Surging Chinese Prices
- Credit Suisse is the Latest Swiss Bank to Disappoint
TheFlyOnTheWall.com Headlines
- Omnicom management to meet with JPMorgan
- NetApp volatility elevated into Q3 and growth outlook
- EMRISE and lender amend loan terms; allows dicount payoff up to 30%
- Alexion target raised to $90 from $76 at ThinkEquity
- Actuant management to meet with JPMorgan
BioHealth Investor Headlines
- Can Human Genome Really Double Its Stock Price? (HGSI)
- Alimera Implosion Analysis, What Is Next (ALIM, PSDV)
- Implosion Analysis For Targacept… What Lies Ahead? (TRGT, AZN)
- Rare Analyst Calls With Huge Upside in Vical and VIVUS (VICL, VVUS, BMY)
- Top Biotechs With Upside Ahead of Earnings (GILD, AMLN, ARIA, INCY, JAZZ, DNDN, HGSI, ILMN, AMGN, CELG, BIIB, BMRN, LIFE, REGN, AMLN, CBST, ONXX, THRX, VPHM)
WalletPop Headlines
- Walmart's New Health Food Push: Is It Too Hard to Swallow?
- Newlyweds, Don't Let the IRS Spoil Your Honeymoon
- Bonds Are a 'Safe' Investment: A Big Lie Gets Even Bigger
- Why Groupon Will Never Be Great Again
- Why Used Car Bargains Are Getting Harder to Find
My Portfolios
Track your stocks here!
Find out why more people track their portfolios on AOL Money & Finance then anywhere else.
BloggingStocks Partners
More from AOL Money & Finance
- Business News
- Stock Screener
- Stock Quotes
- Stock Charts
- Banking
- Identity Theft
- DJIA
- Debt Management
- Loans
- Auto Loan
- Mortgages
- Taxes
- Retirement
- Insurance
- Small Business
- Earnings
- Tech News
- Tax Forms
- Tax Deductions
- Tax Credit
- Tax Audit
- Tax Advice
- Stock Ticker
- Stock Brokers
- Resume Builder
- Pig Flu
- Online Tax Filing
- Madoff
- Investing For Retirement
- Income Tax
- Historical Stock Prices
- GOOG
- ETF Investing
- Deals
- DailyFinance
- Crude Oil Prices
- Credit Score Calculator
- Common Tax Filing Mistakes
- AMT
BioHealth Investor Headlines
- Can Human Genome Really Double Its Stock Price? (HGSI)
- Alimera Implosion Analysis, What Is Next (ALIM, PSDV)
- Implosion Analysis For Targacept… What Lies Ahead? (TRGT, AZN)
- Rare Analyst Calls With Huge Upside in Vical and VIVUS (VICL, VVUS, BMY)
- Top Biotechs With Upside Ahead of Earnings (GILD, AMLN, ARIA, INCY, JAZZ, DNDN, HGSI, ILMN, AMGN, CELG, BIIB, BMRN, LIFE, REGN, AMLN, CBST, ONXX, THRX, VPHM)
The Money Man Behind Rick Santorum: Who Is Foster S. Friess?
Savings Experiment: Snow Removal

